Swedish biotech Axelar's lung cancer drug failed to beat out standard docetaxel in a mid-stage trial, but bankroller Karolinska Development isn't giving up, planning to keep studying the drug in hopes of finding a partner.
Tesaro touted positive results for the primary endpoints laid out for the late-stage program it had underway for its top cancer drug prospect rolapitant, but investors soured on the drug after it failed to score secondary goals and drove the biotech's shares down by a hefty 22% this morning.
Vertex Pharmaceuticals' piecemeal approach to the world's cystic fibrosis sufferers took a hit as Kalydeco failed to meet its primary endpoint in a Phase III trial on patients with one form of the disease, sending the company's shares down as much as 6% premarket on Thursday morning before an eventual rebound.
Gilead unveiled a package of stellar late-stage cure rates for its closely-watched hepatitis C combination of the newly approved "nuke" Sovaldi (sofosbuvir) and the NS5A inhibitor ledipasvir, putting it on a short path to the FDA with a new drug application planned for the first quarter of the coming year.
Onconova Therapeutics' shares took a 16% beating Tuesday night after the company's top prospect, rigosertib, failed a Phase III trial in patients with pancreatic cancer.
Amgen's PCSK9-blocking evolocumab hit its primary endpoints in a Phase III study, the company said, bringing down bad cholesterol and stirring fresh hope for the company as it races with Pfizer, Sanofi and others to cash in with a new approach to cardiovascular treatment.
After a steady drumbeat of setbacks over the past two years, the Winston-Salem, NC-based biotech says it will tamp down the last spade of dirt on TC-5619 after the therapy--which already failed a study for ADHD--flunked the primary as well as secondary endpoints in a Phase IIb study for schizophrenia.
Come January, Italy's CROS NT will have a new CEO, as Andrew MacGarvey will take the reins from longtime chief Paolo Morelli.
Global pharma giant Bayer has inked a three-year deal with the University of Texas' MD Anderson Cancer Center to run clinical trials, matching its investigators with patient-serving oncologists in a deep-seated collaboration.
AbbVie's PARP inhibitor veliparib improved outcomes for women with triple-negative breast cancer in a new investigator-sponsored study, charting a 52% complete response rate.